Therapeutic efficacy and safety of domestic bortezomibˉbased chemotherapy in treatment of multiple myeloma
10.3760/cma.j.issn.1009ˉ9921.2019.05.003
- VernacularTitle:国产硼替佐米为基础的化疗方案治疗多发性骨髓瘤效果及安全性分析
- Author:
Haohao HAN
1
;
Lijie HAN
;
Feifei WU
;
Silin GAN
;
Jie MA
;
Shengmei CHEN
;
Chong WANG
;
Yanfang LIU
;
Haizhou XING
;
Zhongxing JIANG
;
Xinsheng XIE
;
Yingmei LI
;
Weijie CAO
;
Ling SUN
;
Hui SUN
Author Information
1. 郑州大学第一附属医院血液科 450052
- Keywords:
Multiple myeloma;
Bortezomib;
Drug therapy,combination;
Adverse reactions
- From:
Journal of Leukemia & Lymphoma
2019;28(5):268-272
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the efficacy and safety of domestic bortezomibˉbased chemotherapy for patients with multiple myeloma (MM). Methods The clinical data of 60 MM patients treated with domestic bortezomibˉbased chemotherapy regimen (the observation group) in the First Affiliated Hospital of Zhengzhou University from April 2018 to October 2018 were retrospectively analyzed, which were compared with 112 MM patients treated with original treatment regimen (the control group) at the same hospital from November 2010 to November 2014. According to the disease stage, the patients were divided into newly diagnosed MM (NDMM) group and relapsed refractory MM (RRMM) group, and efficacy and adverse reactions of domestic bortezomib were evaluated. Results The total response rate (ORR) of the observation group was 71.7% (43/60), severe complete response (sCR) + complete response (CR) rate was 16.7% (10/60), very good partial response (VGPR) rate was 18.3% (11/60), and partial response (PR) rate was 36.7% (22/60). The ORR of NDMM group (45 cases) and RRMM group (15 cases) was 82.2% (37/45) and 40.0% (6/15), respectively, and the difference was statistically significant (χ2＝ 9.877, P < 0.05). There was no significant difference between ISS stage Ⅰ+Ⅱ and stage Ⅲ [ORR: 75.7% (28/37) vs. 65.2% (15/23), respectively; χ2＝0.764, P >0.05]. ORR and CR rates in the NDMM group and RRMM group of the observation group and the control group were not statistically different (all P>0.05). In the treatment of bortezomibˉbased chemotherapy, the common adverse reaction was peripheral neuropathy, mostly belonging to grade 1-2. Other side effects included hematocytopenia, gastrointestinal events and herpes zoster, which could be alleviated or restored to normality after supportive treatments. One patient died of pulmonary infection, respiratory failure and septic shock during the intermittent period of chemotherapy. Conclusion ORR of domestic bortezomibˉbased chemotherapy in treatment of the patients with MM is high, and the incidence of adverse reactions shows no significant increase compared with original drugs.
